{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268046","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.981861+00:00","generated_at":"2026-05-17T00:01:50.675135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neumora Q3 net loss $56.8M; cash $171.5M; pipeline updates on NMRA-215, M4 PAMs, NMRA-511","bullets":["Net loss of $56.8M for Q3 2025 vs $72.5M in Q3 2024; R&D expense down to $40.5M from $60.6M.","Cash, equivalents, and marketable securities $171.5M; expects to fund operations into 2027.","Drew $40M non-dilutive capital from K2 HealthVentures facility.","NMRA-215 (NLRP3 inhibitor) showed class-leading weight loss in DIO mouse models; Phase 1 expected Q1 2026.","NMRA-511 Phase 1b data in Alzheimer's agitation expected around year-end; navacaprant KOASTAL topline in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268046","json":"https://secwatch.observer/filing/0001193125-25-268046.json","markdown":"https://secwatch.observer/filing/0001193125-25-268046.md","text":"https://secwatch.observer/filing/0001193125-25-268046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/0001193125-25-268046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:01:50.675135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}